There was a significant interaction for major or NMCR bleeding in patients with PAD treated with rivaroxaban compared with warfarin ( HR : 1.40 , 95 % CI : 1.06-1 .86 ) compared with those without PAD ( HR : 1.03 , 95 % CI : 0.95-1 .11 ; interaction P = 0.037 ) .